Maximizing Analgesia to Reduce Pain in Knee Osteoarthritis

• Status: Recruiting
• Trial end date: 2022-11-15
• Target enrollment: 0
• Participant gender: All

Summary

This research is being done to evaluate whether combining medications that are FDA approved, but have not yet been approved for combination treatment, can be effective in reducing pain.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Collaborator: National Institutes of Health (NIH)
• Treatments: Central Nervous System Stimulants

Criteria

Inclusion Criteria:

• Diagnosis of knee osteoarthritis

• Urine sample tests negative for common illicit substances of abuse (e.g., cannabis)

• Medically cleared to take study medications

• Are not pregnant or breast feeding

• Willing to comply with the study protocol.

Exclusion Criteria:

• Pain other than Knee Osteoarthritis

• Taking opioids for pain

• Prescribed and taking gabapentinoid, Tricyclic Antidepressants (TCA), venlafaxine, duloxetine, stimulants or benzodiazepines

• Presence of any clinically significant medical/psychiatric illness judged by the investigators to put subject at elevated risk for experiencing an adverse event

• Known allergy to the blinded study medications